$BIIB F/Y GUIDANCE 🔸 Sees ADJ EPS $16.10 to $16.60, saw $15.75 to $16.25 RESULTS: Q3 🔸 ADJ EPS $4.08 vs. $4.36 y/y 🔸 Revenue $2.47B, -2.5% y/y, EST $2.43B 🔸 Multiple sclerosis revenue $1.05B, EST $1.06B 🔸 Total Fumarate rev. $390.9M, -3.5% y/y, EST $348.2M 🔸 Tecfidera revenue $232.8M, -2.8% y/y, EST $229.5M 🔸 Vumerity rev. $158.1M, -4.5% y/y, EST $169.9M 🔸 Total Interferon rev. $237.5M, EST $245.5M 🔸 Avonex revenue $176.2M, -17% y/y, EST $178.4M 🔸 Plegridy revenue $61.3M, EST $62.9M 🔸 Tysabri revenue $406.1M, -11% y/y, EST $409.6M 🔸 Fampyra rev. $19.4M, -3% y/y, EST $19.8M 🔸 Spinraza revenue $381.4M, -15% y/y, EST $435.4M 🔸 Benepali rev. $118.1M, +4.7% y/y, EST $112.5M 🔸 Imraldi rev. $54.1M, -0.6% y/y, EST $53.9M 🔸 Flixabi Rev. $16.2M, -20% y/y, EST $16.2M 🔸 Byooviz revenue $8M, +16% y/y, EST $14.2M, 🔸 ADJ net income $595.7M, -6.3% y/y